Lynn Seely, M.D., has been the CEO of Lyell Immunopharma, Inc. since December 15, 2022, after taking over from Elizabeth Homans. She has an impressive background in medicine and business. Dr. Seely earned her M.D. from the University of Oklahoma...
Lynn Seely, M.D., has been the CEO of Lyell Immunopharma, Inc. since December 15, 2022, after taking over from Elizabeth Homans. She has an impressive background in medicine and business. Dr. Seely earned her M.D. from the University of Oklahoma College of Medicine and has experience in high-level positions at several biotech companies. Before coming to Lyell, she was CEO of Myovant Sciences and served as Chief Medical Officer at Medivation. Dr. Seely brings over 15 years of experience in the healthcare industry, focusing on innovative therapies and operations. Under her leadership, Lyell aims to advance the field of immunotherapy. Interestingly, she secured a large stock option grant of 7.5 million shares when she joined, signaling strong confidence in her role and the company's future. Dr. Seely not only focuses on science but also understands the business side well, blending her medical expertise with a clear vision for growth in the biotech landscape.